InspireMD, Inc. — FY2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. This is an annual report, not a standalone fourth-quarter report; the filing does not provide a clear set of Q4-only financial results. Financial statement amounts below are in U.S. dollars, generally in millions unless noted.
Business context
InspireMD develops and commercializes MGuard, a stent platform with a micron-mesh sleeve intended to reduce embolic debris during coronary stenting. The company sells primarily through distributors outside the United States. Its products had CE Mark authorization in Europe, but none were FDA-approved at year-end. The March 2011 share exchange made InspireMD Ltd. the operating business of the public company; the financial history presented is that of InspireMD Ltd. and is accounted for as a reverse recapitalization.
Financial results and liquidity
| Metric | FY2011 | FY2010 | Change / context |
|---|---|---|---|
| Revenue | $6.004 | $4.949 | Up 21.3%; growth mainly from increased sales volume, including initial shipments to India. |
| Cost of revenue | $3.011 | $2.696 | |
| Gross profit / margin | $2.993 / 49.9% | $2.253 / 45.5% | Margin improved with lower unit production costs and scale. |
| Operating expenses | $16.722 | $5.472 | Increase driven especially by share-based compensation and higher clinical, sales, and public-company costs. |
| Operating loss | $(13.729) | $(3.219) | |
| Net loss | $(14.665) | $(3.420) | Loss per share was $(0.24), versus $(0.07). |
| Cash used in operating activities | $(6.003) | $(2.710) | Higher operating cash use accompanied increased spending and working-capital needs. |
| Cash and cash equivalents at year-end | $5.094 | $0.636 | Increase primarily reflected equity financing. |
| Working capital | $6.389 | $(0.053) | Current assets were 2.8 times current liabilities at year-end. |
| Total assets / equity | $10.465 / $6.754 | $4.355 / $(0.914) | Equity turned positive following financing and share-based issuances. |
Operating expenses included $2.474 million of R&D, $1.973 million of selling and marketing, and $12.275 million of general and administrative expense. Share-based compensation was $9.590 million, including $8.542 million recorded in G&A. Financial expense was $0.934 million, including a $0.624 million fair-value increase in the convertible debenture liability before conversion or repayment.
Financing activities provided $10.669 million, primarily from share and warrant issuances and option exercises. The company reported $94,000 of remaining bank-loan principal at year-end, due in January 2012; the filing says it was paid that month. The convertible debenture balance was converted in part and the remaining $1.0 million principal was repaid in May 2011. Management expected year-end funds and anticipated revenue to fund operations until at least May or June 2013, while warning that further capital would be needed to fund subsequent operations or broader expansion.
Material changes versus FY2010
- Revenue rose 21.3%, while gross margin expanded from 45.5% to 49.9%.
- Net loss widened to $14.665 million from $3.420 million, largely reflecting $9.590 million of share-based compensation and increased clinical-development, commercial, and public-company costs.
- R&D spending increased to $2.474 million from $1.338 million, principally due to clinical-trial costs. Selling and marketing expense rose to $1.973 million from $1.236 million.
- G&A increased to $12.275 million from $2.898 million, including a substantial rise in share-based compensation and costs of being a U.S. reporting company.
- Cash increased to $5.094 million from $0.636 million following equity financings; operating cash use also increased.
- The company raised approximately $12.1 million in net proceeds from equity issuances and option exercises during 2011, while issuing additional shares and warrants.
Outlook, risks, contingencies, and unusual items
- Clinical and regulatory execution: Management planned a U.S. FDA study of approximately 800 patients and a multinational MASTER trial. As of February 29, 2012, 201 of 432 planned MASTER participants had enrolled. Trial schedules had experienced delays, including delays in local ethics approvals and funding. The filing gives differing FDA timing references: a sales discussion targets approval in 2014, while the milestone schedule points to 2015; investors should not treat either date as assured.
- Trial costs and funding: The company budgeted $8.5 million for the FDA trial and expected to pay Harvard Clinical Research Institute approximately $10 million to conduct a study, subject to scope adjustments and other costs. Management stated available resources would not fund all objectives indefinitely; insufficient or unfavorable financing could delay or halt trials and dilute shareholders.
- Commercial concentration and execution: Three distributors accounted for 39% of revenue in 2011: India 18%, Israel 12%, and Spain 9%. Several distributors, including the Indian, Spanish, and Polish distributors, missed 2011 minimum purchase requirements, although the company did not terminate their exclusivity. The filing reports 2011 sales of approximately $6 million and less than 1% of the acute myocardial infarction solutions market.
- Product evidence: Management highlighted favorable results from a meta-analysis comparing MGuard outcomes with historical control studies. These were not presented as a randomized head-to-head result; the planned MASTER and FDA trials remain important tests of safety and efficacy.
- Legal contingencies: A former employee sought approximately $428,000 plus options to acquire 2,029,025 shares; the company said additional loss was not probable or estimable. A finder claim resulted in a $327,000 provision in 2011. Other disputed claims seek compensation or options, and the company said outcomes could not be assessed for some claims. A separate possible Israeli securities-law violation remained unresolved with the Israel Securities Authority; the filing describes potential penalties.
- Other risks: The company depends on key suppliers and has limited manufacturing capacity; it faces larger competitors, patent litigation risk, foreign-exchange exposure, and reimbursement uncertainty. It does not hedge currency risk. It also disclosed that approximately 59.3 million shares could become saleable under Rule 144 after April 6, 2012, potentially increasing market overhang.
- Unusual accounting and governance items: The year included substantial non-cash stock awards, notably awards to the chairman that contributed materially to expense. Management and the auditor concluded internal control over financial reporting was effective as of year-end; the auditor issued an unqualified opinion on the financial statements and controls.
Most important facts for investors to verify
- Reconcile the FDA approval and U.S. sales timetable, and track enrollment, completion, and results of the MASTER and FDA trials.
- Assess cash burn against the stated May/June 2013 runway, trial obligations, and the approximately $10 million Harvard study fee; confirm whether additional financing is required.
- Monitor distributor purchase performance, renewals, customer concentration, receivable collections, and the reliability of reported revenue and return estimates.
- Review the status and potential financial or share-dilution impact of outstanding litigation, disputed option claims, and the Israeli securities-law inquiry.
- Evaluate the scale and terms of outstanding options and warrants, potential Rule 144 sales, and any planned reverse stock split or exchange listing efforts.
- Distinguish clinical findings based on historical comparisons from results of controlled trials, and confirm regulatory approvals and reimbursement access market by market.